CARB-X IS FUNDING BASILEA PHARMACEUTICA TO DEVELOP A NEW CLASS OF ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA

CARB-X is awarding Basilea Pharmaceutica International (SIX: BSLN), Basel, Switzerland, up to US $2.7 million to develop a novel class of antibiotics to treat Gram-negative bacterial infections. Gram-negative bacteria, often called ‘superbugs’ because they have developed resistance at an alarming pace to existing antibiotics, kill an estimated 700,000 people each year around the world.